Pentoxifylline for bipolar depression: A pilot study

Nelson B Rodrigues¹, Simina Toma², Roger S McIntyre³, Sebastian Badulescu⁴, Benjamin I Goldstein⁵, Bradley J MacIntosh⁶, Rodrigo B Mansur⁷, Joshua D Rosenblat⁸

Affiliations

¹ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Psychology, University of Windsor, Windsor, ON, Canada.
² Department of Psychiatry, Sunnybrook Health Science Center, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
³ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Canada; University of Toronto, Toronto, ON, Canada.
⁴ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
⁵ Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, ON, Canada.
⁶ Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, ON, Canada; Sandra E Black Centre for Brain Resilience and Recovery, Department of Medical Biophysics, University of Toronto, ON, Canada.
⁷ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁸ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Electronic address: joshua.rosenblat@uhn.ca.

PMID: 39226874
DOI: 10.1016/j.psychres.2024.116152

Pentoxifylline for bipolar depression: A pilot study

Nelson B Rodrigues et al. Psychiatry Res. 2024 Nov.

. 2024 Nov:341:116152.

doi: 10.1016/j.psychres.2024.116152. Epub 2024 Aug 29.

Authors

Nelson B Rodrigues¹, Simina Toma², Roger S McIntyre³, Sebastian Badulescu⁴, Benjamin I Goldstein⁵, Bradley J MacIntosh⁶, Rodrigo B Mansur⁷, Joshua D Rosenblat⁸

Affiliations

¹ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Psychology, University of Windsor, Windsor, ON, Canada.
² Department of Psychiatry, Sunnybrook Health Science Center, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
³ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Canada; University of Toronto, Toronto, ON, Canada.
⁴ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
⁵ Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, ON, Canada.
⁶ Centre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, Toronto, ON, Canada; Sandra E Black Centre for Brain Resilience and Recovery, Department of Medical Biophysics, University of Toronto, ON, Canada.
⁷ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁸ Poul Hansen Depression Centre, Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Electronic address: joshua.rosenblat@uhn.ca.

PMID: 39226874
DOI: 10.1016/j.psychres.2024.116152

No abstract available

Keywords: Anti-inflammatory; Bipolar disorder; Depression; Inflammation; Mood disorder; Pentoxifylline.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Joshua D Rosenblat has received research grant support from the Canadian Institute of Health Research (CIHR), Physician Services Inc (PSI) Foundation, Labatt Brain Health Network, Brain and Cognition Discovery Foundation (BCDF), Canadian Cancer Society, Canadian Psychiatric Association, Academic Scholars Award, American Psychiatric Association, American Society of Psychopharmacology, University of Toronto, University Health Network Centre for Mental Health, Joseph M. West Family Memorial Fund and Timeposters Fellowship and industry funding for speaker/consultation/research fees from iGan, Boehringer Ingelheim, Janssen, Allergan, Lundbeck, Sunovion and COMPASS. Dr. Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC); speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie and Atai Life Sciences. Dr. S. Roger McIntyre is a CEO of Braxia Scientific Corp. All other co-authors report no conflicts of interest.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pentoxifylline for bipolar depression: A pilot study

Affiliations

Pentoxifylline for bipolar depression: A pilot study

Authors

Affiliations

Conflict of interest statement

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical